U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H11Cl2N.ClH
Molecular Weight 264.579
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOV-102677 HYDROCHLORIDE

SMILES

Cl.[H][C@@]12C[C@@]1(CNC2)C3=CC(Cl)=C(Cl)C=C3

InChI

InChIKey=KAGBHVBIOJBGBD-IBYXRORRSA-N
InChI=1S/C11H11Cl2N.ClH/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11;/h1-3,8,14H,4-6H2;1H/t8-,11+;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C11H11Cl2N
Molecular Weight 228.118
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18539031 | https://www.ncbi.nlm.nih.gov/pubmed/17908267

DOV-102,677 is a “Triple” Monoamine Neurotransmitter Uptake Inhibitor being developed by Merck for treating the major depressive disorder. In preclinical studies, DOV 102,677 increased extracellular levels of DA and 5-HT in the prefrontal cortex at 100 min after administration. DA levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. NE levels increased linearly to a maximum of 240 min post-dosing. Consistent with these increases in NE levels, the density of β-adrenoceptors was selectively decreased in the cortex of rats treated with DOV 102,677. DOV 102,677 dose-dependently reduced the amount of time spent immobile by rats in the forced swim test, a model predictive of antidepressant activity, with a minimum effective dose (MED) of 20 mg/kg and a maximal efficacy comparable to imipramine. However, phase I clinical trials for treatment Depression in the USA was discontinued. Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
103.0 nM [IC50]
129.0 nM [IC50]
133.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1780 ng/mL
20 mg/kg single, oral
dose: 20 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOV-102677 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.5 h
20 mg/kg single, oral
dose: 20 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOV-102677 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors.
2008 Jul 1
Patents

Patents

Sample Use Guides

Rat: 20 mg/kg per day, PO, 35 days.
Route of Administration: Oral
HEK-hDAT and HEK-hSERT cells were incubated in modified Eagle’s medium supplemented with 5% fetal bovine serum, 5% calf bovine serum, 0.05 U penicillin/streptomycin and puromycin (2 μg/mL). HEK-hNET cells were incubated in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 0.05 U penicillin/streptomycin and geneticin (300 μg/mL). Cells were grown until confluent on 150 mm diameter tissue culture dishes in a humidified 10% CO2 environment at 37◦C. [125I]RTI-55 (Perkin Elmer Life Sciences, Boston, MA) was used in competition binding assays characterizing DOV 102,677 affinity for the three monoamine neurotransmitter transporters. Aliquots (50 μL) of the suspended cells were added to assay tubes containing drugs and Krebs-HEPES assay buffer in a final assay volume of 0.5 mL. Uptake inhibition studies were conducted using triplicate determinations for each test substance. [3H]DA, [3H]5-HT, or [3H]NE (Perkin Elmer Life Sciences, Boston, MA, 56, 26.9, 60 Ci/mmol, respectively, 20 nM final concentration) was added after a 10 min pre-incubation of the isolated cells in a 25◦C water bath, and the assay incubated an additional 10 min. The reaction was terminated by vacuum filtration over Whatman GF/C filters using a 96-well Tomtec cell harvester (Hamden, CT). Specific uptake was defined as the difference in uptake observed in the absence and presence of 5 μM mazindol (hDAT and hNET) or 5 μM imipramine (hSERT).
Substance Class Chemical
Created
by admin
on Sat Dec 16 14:23:38 GMT 2023
Edited
by admin
on Sat Dec 16 14:23:38 GMT 2023
Record UNII
8WR4Q5ZGU3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOV-102677 HYDROCHLORIDE
Code English
3-AZABICYCLO(3.1.0)HEXANE, 1-(3,4-DICHLOROPHENYL)-, HYDROCHLORIDE, (1S,5R)-
Systematic Name English
DOV-102,677 HYDROCHLORIDE
Code English
3-AZABICYCLO(3.1.0)HEXANE, 1-(3,4-DICHLOROPHENYL)-, HYDROCHLORIDE (1:1), (1S,5R)-
Systematic Name English
(-)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO(3.1.0)HEXANE HYDROCHLORIDE
Systematic Name English
(1S,5R)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO(3.1.0)HEXANE HYDROCHLORIDE
Systematic Name English
(-)-AMITIFADINE HYDROCHLORIDE
Common Name English
Code System Code Type Description
CAS
500733-69-7
Created by admin on Sat Dec 16 14:23:38 GMT 2023 , Edited by admin on Sat Dec 16 14:23:38 GMT 2023
PRIMARY
PUBCHEM
16072154
Created by admin on Sat Dec 16 14:23:38 GMT 2023 , Edited by admin on Sat Dec 16 14:23:38 GMT 2023
PRIMARY
FDA UNII
8WR4Q5ZGU3
Created by admin on Sat Dec 16 14:23:38 GMT 2023 , Edited by admin on Sat Dec 16 14:23:38 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY